Affimed Says FDA Granted Fast Track Designation To Combination Of Its Innate Cell Engager AFM24 With Atezolizumab For EGFR Wild-Type Non-Small Cell Lung Cancer
Author: Benzinga Newsdesk | May 29, 2024 06:32am
This is for the treatment of patients with advanced and/or metastatic non-small cell lung cancer (NSCLC) not harboring any activating EGFR mutations (EGFR wild-type) after progression on PD-(L)1 targeted therapy and platinum-based chemotherapy. Data from the AFM24-102 study in this patient population will be presented at the upcoming annual meeting of the American Society of Clinical Oncology on June 1, 2024.
Posted In: AFMD